StreetInsider.com News Articles

Haemonetics (HAE) PT Raised to $142 at Baird

Thu, 15 Oct 2026 07:22:10 -0400

Baird analyst David Rescott raised the price target on Haemonetics (NYSE: HAE) to $142.00 (from $119.00) while maintaining a Outperform rating.

Haemonetics (HAE) PT Raised to $140 at Mizuho

Fri, 09 Oct 2026 06:37:34 -0400

Mizuho analyst Anthony Petrone raised the price target on Haemonetics (NYSE: HAE) to $140.00 (from $95.00) while maintaining a Outperform rating.

Haemonetics stock jumps on CSL Plasma device rollout plan

Thu, 08 Oct 2026 09:56:09 -0400

Haemonetics Corp. stock climbed 16.1% in morning trading on Thursday after CSL Plasma said it plans to deploy Haemonetics' NexSys PCS devices with Persona PLUS technology across all of its current U.S. plasma collection centers by the end of 2027.

CSL Plasma disclosed the rollout plan in an 8-K regulatory filing on Thursday. The commitment covers more than 300 U.S. donation centers operated by CSL.

The two companies had signed a non-exclusive supply agreement on Aug. 18, 2026, which included no minimum volume commitments. The latest announcement represents a shift to a full-network commitment.

BTIG raised its price target on Haemonetics to $130

Haemonetics (HAE) PT Raised to $130 at BTIG

Thu, 08 Oct 2026 09:17:25 -0400

(Updated - October 8, 2026 9:17 AM EDT)

BTIG analyst Marie Thibault raised the price target on Haemonetics (NYSE: HAE) to $130.00 (from $110.00) while maintaining a Buy rating.

The analyst commented: "In mid-August, Haemonetics disclosed a new, non-exclusive supply agreement with CSL Plasma Inc. (CSL-AX, Not Rated), allowing CSL to use HAE's NexSys PCS devices with Persona PLUS technology and purchase related disposables in the U.S. (see note here). This morning, we received new detail on this agreement: CSL confirmed it anticipates transitioning to HAE's platform across all of its current U.S. plasma collection centers, with completion targeted by end of

Haemonetics (HAE) PT Raised to $130 at BTIG

Thu, 08 Oct 2026 09:17:25 -0400

(Updated - October 8, 2026 9:17 AM EDT)

BTIG analyst Marie Thibault raised the price target on Haemonetics (NYSE: HAE) to $130.00 (from $110.00) while maintaining a Buy rating.

Haemonetics stock surges 17% on CSL Plasma supply deal update

Thu, 08 Oct 2026 08:50:31 -0400

Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.

CSL announced on October 8, 2026, that it expects to complete the rollout of Haemonetics' NexSys PCS® devices with Persona® PLUS technology and related disposables by the end of calendar year 2027, according to an 8-K filing. CSL informed Haemonetics that it currently anticipates the transition will occur at all of its U.S. plasma collection centers.

The companies initially entered into the non-exclusive supply agreement on August 18, 2026. Under the deal,

Haemonetics stock surges 17% on CSL Plasma supply deal update

Thu, 08 Oct 2026 08:50:31 -0400

Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.

The companies initially entered into the non-exclusive supply agreement on August 18, 2026. Under the deal,

Haemonetics stock surges 17% on CSL Plasma supply deal update

Thu, 08 Oct 2026 08:50:31 -0400

Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.

The companies initially entered into the non-exclusive supply agreement on August 18, 2026. Under the deal,

Haemonetics stock surges 17% on CSL Plasma supply deal update

Thu, 08 Oct 2026 08:50:31 -0400

Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.

The companies initially entered into the non-exclusive supply agreement on August 18, 2026. Under the deal,

Form 8-K HAEMONETICS CORP For: Oct 08

Thu, 08 Oct 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20261008/27163188.html

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

Wed, 30 Sep 2026 16:05:00 -0400

BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 5, 2026.

The call

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

Wed, 30 Sep 2026 16:05:00 -0400

The call

Haemonetics (HAE) spreader of 500 contracts of November 115 and 130 calls as share price up 2.5%

Thu, 17 Sep 2026 15:03:53 -0400

Haemonetics (NYSE: HAE) 30-day option implied volatility is at 34; compared to its 52-week range of 27 to 73 with a focus on a spreader of 500 contracts of November 115 and 130 calls as share price up 2.5%.

Citi upgrades Haemonetics to Buy, raises price target to $123

Thu, 17 Sep 2026 05:02:18 -0400

(Updated - September 17, 2026 5:02 AM EDT)

Citi analyst Joanne Wuensch upgraded Haemonetics (NYSE: HAE) from Neutral to Buy, raising the price target to $123 from $92, following a new supply agreement between Haemonetics and CSL.

Haemonetics entered into a non-exclusive supply agreement with CSL on August 14, 2026, for its NexSys devices with Persona and PLUS technology in the U.S. Haemonetics already holds an agreement with CSL outside the U.S.

The agreement follows a period of separation that began in early 2021, when CSL terminated its prior agreement with Haemonetics in favor of a competitor's apheresis device. Several amendments and two

Orchestra BioMed receives $6.1M milestone payment from Vivasure deal

Tue, 15 Sep 2026 08:30:36 -0400

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced it received a $6.1 million milestone payment on Sept. 14, 2026, stemming from the acquisition of Vivasure Medical Limited by Haemonetics Corporation (NYSE: HAE).

The payment represents the first milestone installment tied to the transaction and follows an approximately $5 million upfront payment received in January 2026. Combined, the two payments bring total cash proceeds received by Orchestra BioMed to approximately $11 million.

Haemonetics completed its acquisition of Vivasure, an Ireland-based medical device company focused on percutaneous vessel closure technology, on Jan. 9, 2026. Vivasure had been a strategic holding of Orchestra BioMed since the

Orchestra BioMed receives $6.1M milestone payment from Vivasure deal

Tue, 15 Sep 2026 08:30:36 -0400

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Azenta names board member as interim CEO after Marotta resigns

Mon, 24 Aug 2026 08:01:03 -0400

Azenta, Inc. (Nasdaq: AZTA) announced that John Marotta has resigned as president, CEO, and director, and that board member Dr. Martin Madaus has been appointed interim president and CEO, according to a company press release dated Aug. 24, 2026.

Dr. Madaus has served on the Azenta board since 2024 and is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG). He has previously held CEO roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.